Literature DB >> 20651469

Growth hormone secretion among adult patients with Prader-Willi syndrome due to different genetic subtypes.

G Grugni1, D Giardino, A Crinò, F Malvestiti, L Ballarati, G Di Giorgio, P Marzullo.   

Abstract

BACKGROUND: Patients with Prader-Willi syndrome (PWS) due to maternal uniparental disomy of the chromosome 15 (UPD15) have fewer facial features, less hypopigmentation and higher levels of psychosis compared to subjects with deletion in chromosome 15 (del15q11-q13). PWS individuals carrying the larger type I (TI) deletion suffer from greater behavioral problems than patients with the smaller type II (TII) deletion. Few data are currently available on the relationship existing between endocrine abnormalities in PWS subjects and the different genotypes. AIM: To investigate the stimulated GH levels in PWS patients with different types of deletion and those with UPD15. SUBJECTS AND METHODS: Thirty-seven patients, 14 males, aged 17.5-41.2 yr, with PWS due to TI deletion (no.=6), TII deletion (no.=15) or UPD15 (no.=16), were studied. Pituitary GH secretion was evaluated by dynamic testing with GHRH+arginine.
RESULTS: Both the mean peak GH response and the integrated GH secretion (GH area under the curve and GH area under the curve corrected for basal values) for the UPD15 patients (4.6 ± 1.6 μg/l, 241.6 ± 71.7 μg/l/h and 228.3 ± 71.6 μg/l/h, respectively) were lower than that observed in all subjects with del15q11-q13 (9.1±1.8 μg/l, 547.0 ± 132.3 μg/l/h and 514.9 ± 127.6 μg/l/h: p<0.005), as well as in TI (7.7 ± 1.2 μg/l: p<0.02; 424.2 ± 88.8 and 393.4 ± 88.8 μg/l/h: p<0.05) and TII (9.6 ± 2.6 μg/l, 587.9 ± 174.2 μg/l/h and 555.4 ± 167.6 μg/l/h: p<0.01) deletion groups. TI and TII groups had similar stimulated GH levels and integrated GH secretion.
CONCLUSIONS: Our results point at differentiating the pattern of GH secretion by genetic subtypes, with higher GH responses in typical deletion subjects when compared to patients with UPD15.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20651469     DOI: 10.3275/7203

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  30 in total

Review 1.  Serum levels of insulin-like growth factor I and its binding proteins in health and disease.

Authors:  Anders Juul
Journal:  Growth Horm IGF Res       Date:  2003-08       Impact factor: 2.372

2.  Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults.

Authors:  G Aimaretti; G Corneli; P Razzore; S Bellone; C Baffoni; E Arvat; F Camanni; E Ghigo
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

3.  Prader-Willi syndrome: intellectual abilities and behavioural features by genetic subtype.

Authors:  Katja M Milner; Ellen E Craig; Russell J Thompson; Marijcke W M Veltman; N Simon Thomas; Sian Roberts; Margaret Bellamy; Sarah R Curran; Caroline M J Sporikou; Patrick F Bolton
Journal:  J Child Psychol Psychiatry       Date:  2005-10       Impact factor: 8.982

4.  Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome.

Authors:  G Grugni; P Marzullo; L Ragusa; A Sartorio; G Trifirò; A Liuzzi; A Crinò
Journal:  Clin Endocrinol (Oxf)       Date:  2006-10       Impact factor: 3.478

Review 5.  Prader-Willi syndrome: clinical genetics, cytogenetics and molecular biology.

Authors:  Douglas C Bittel; Merlin G Butler
Journal:  Expert Rev Mol Med       Date:  2005-07-25       Impact factor: 5.600

6.  Pleiotropic role of IGF-I in obesity hypoventilation syndrome.

Authors:  Denis Monneret; Jean-Christian Borel; Jean-Louis Pepin; Renaud Tamisier; Nathalie Arnol; Patrick Levy; Patrice Faure
Journal:  Growth Horm IGF Res       Date:  2009-12-14       Impact factor: 2.372

7.  Maladaptive behavior differences in Prader-Willi syndrome due to paternal deletion versus maternal uniparental disomy.

Authors:  E M Dykens; S B Cassidy; B H King
Journal:  Am J Ment Retard       Date:  1999-01

8.  Behavioral differences among subjects with Prader-Willi syndrome and type I or type II deletion and maternal disomy.

Authors:  Merlin G Butler; Douglas C Bittel; Nataliya Kibiryeva; Zohreh Talebizadeh; Travis Thompson
Journal:  Pediatrics       Date:  2004-03       Impact factor: 7.124

9.  Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment.

Authors:  Charlotte Höybye
Journal:  Growth Horm IGF Res       Date:  2004-02       Impact factor: 2.372

10.  Prader-Willi syndrome: consensus diagnostic criteria.

Authors:  V A Holm; S B Cassidy; M G Butler; J M Hanchett; L R Greenswag; B Y Whitman; F Greenberg
Journal:  Pediatrics       Date:  1993-02       Impact factor: 7.124

View more
  8 in total

1.  Approach to the child with prader-willi syndrome.

Authors:  Jennifer L Miller
Journal:  J Clin Endocrinol Metab       Date:  2012-11       Impact factor: 5.958

Review 2.  GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome.

Authors:  Cheri L Deal; Michèle Tony; Charlotte Höybye; David B Allen; Maïthé Tauber; Jens Sandahl Christiansen
Journal:  J Clin Endocrinol Metab       Date:  2013-03-29       Impact factor: 5.958

Review 3.  Growth Hormone Therapy in Adults with Prader-Willi Syndrome.

Authors:  Karen S Vogt; Jill E Emerick
Journal:  Diseases       Date:  2015-04-16

4.  Prevalence of growth hormone (GH) deficiency in previously GH-treated young adults with Prader-Willi syndrome.

Authors:  Stephany H Donze; Layla Damen; Janiëlle A E M van Alfen-van der Velden; Gianni Bocca; Martijn J J Finken; Gera J G Hoorweg-Nijman; Petr E Jira; Mariëtte van Leeuwen; Anita C S Hokken-Koelega
Journal:  Clin Endocrinol (Oxf)       Date:  2019-04-30       Impact factor: 3.478

5.  Health Problems in Adults with Prader-Willi Syndrome of Different Genetic Subtypes: Cohort Study, Meta-Analysis and Review of the Literature.

Authors:  Anna G W Rosenberg; Charlotte M Wellink; Juan M Tellez Garcia; Karlijn Pellikaan; Denise H Van Abswoude; Kirsten Davidse; Laura J C M Van Zutven; Hennie T Brüggenwirth; James L Resnick; Aart J Van der Lely; Laura C G De Graaff
Journal:  J Clin Med       Date:  2022-07-12       Impact factor: 4.964

6.  Endocrine manifestations and management of Prader-Willi syndrome.

Authors:  Jill E Emerick; Karen S Vogt
Journal:  Int J Pediatr Endocrinol       Date:  2013-08-21

7.  Psychiatric illness and intellectual disability in the Prader-Willi syndrome with different molecular defects--a meta analysis.

Authors:  Lin Yang; Guo-dong Zhan; Jun-jie Ding; Hui-jun Wang; Duan Ma; Guo-ying Huang; Wen-hao Zhou
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

Review 8.  Growth hormone therapy for Prader-willi syndrome: challenges and solutions.

Authors:  Graziano Grugni; Alessandro Sartorio; Antonino Crinò
Journal:  Ther Clin Risk Manag       Date:  2016-06-02       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.